Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Current Assets: 2009-2025

Historic Current Assets for Northwest Biotherapeutics (NWBO) over the last 17 years, with Sep 2025 value amounting to $7.2 million.

  • Northwest Biotherapeutics' Current Assets rose 38.64% to $7.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.2 million, marking a year-over-year increase of 38.64%. This contributed to the annual value of $4.1 million for FY2024, which is 1.53% down from last year.
  • As of Q3 2025, Northwest Biotherapeutics' Current Assets stood at $7.2 million, which was up 16.95% from $6.2 million recorded in Q2 2025.
  • Northwest Biotherapeutics' 5-year Current Assets high stood at $17.3 million for Q4 2021, and its period low was $4.1 million during Q4 2024.
  • Its 3-year average for Current Assets is $5.8 million, with a median of $5.0 million in 2024.
  • As far as peak fluctuations go, Northwest Biotherapeutics' Current Assets surged by 266.32% in 2021, and later slumped by 56.23% in 2023.
  • Over the past 5 years, Northwest Biotherapeutics' Current Assets (Quarterly) stood at $17.3 million in 2021, then tumbled by 45.49% to $9.4 million in 2022, then slumped by 56.23% to $4.1 million in 2023, then decreased by 1.53% to $4.1 million in 2024, then skyrocketed by 38.64% to $7.2 million in 2025.
  • Its Current Assets stands at $7.2 million for Q3 2025, versus $6.2 million for Q2 2025 and $4.7 million for Q1 2025.